Thursday 1 October 2020
Home      All news      Contact us      RSS     
wn.com - 2 month ago

Corbus Pharmaceuticals Completes Enrollment in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis

12-month, double-blind, placebo-controlled, multi-national study enrolled 176 participants Topline results expected infourth quarter of 2021 Dermatomyositis is a rare, systemic autoimmune disease with characteristic skin and muscle involvement, serious morbidity, and increased mortality Norwood, MA, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ( Corbus or the Company ), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced the completion of subject enrollment in DETERMINE, a Phase 3 study assessing the efficacy and safety of lenabasum for the treatment of...


Latest News
Hashtags:   

Corbus

 | 

Pharmaceuticals

 | 

Completes

 | 

Enrollment

 | 

DETERMINE

 | 

Phase

 | 

Study

 | 

Lenabasum

 | 

Treatment

 | 

Dermatomyositis

 | 

Sources